Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
1-15 of 4547 results
Asklepios BioPharmaceutical launches new portfolio company Actus Therapeutics
Asklepios BioPharmaceutical has formed Actus Therapeutics, a new portfolio company based on AskBio’s industry-leading gene therapy platform.
Drug Research > Drug Discovery & Development > News
GW Pharmaceuticals reacquires full rights of develop Sativex in US
GW Pharmaceuticals has terminated its previous license agreement with Otsuka Pharmaceutical in relation to Sativex (nabiximols) in the US.
Drug Research > Drug Discovery & Development > News
CMC Biologics signs development and manufacturing deal with Harpoon Therapeutics
CMC ICOS Biologics and Harpoon Therapeutics have signed an agreement to develop and manufacture HPN424, HPN536, and HPN217, representing three TriTAC molecules for the treatment of several human cancers.
Drug Research > Drug Discovery & Development > News
Aeonian Pharmaceuticals secures funding to develop mTORC1 inhibitors
Aeonian Pharmaceuticals, a San Francisco Bay Area-based biopharmaceutical company, has closed a seed financing round led by Apollo Ventures and Life Sciences Company.
Drug Research > Drug Discovery & Development > News
Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant
Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.
Drug Research > Drug Discovery & Development > News
bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy
bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.
Drug Research > Drug Discovery & Development > News
Gilead Sciences to acquire Cell Design Labs in $567m deal
By PBR Staff Writer
Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m.
Drug Research > Drug Discovery & Development > News
GSK to invest £40m in UK's life sciences sector
By PBR Staff Writer
GlaxoSmithKline (GSK) has agreed to invest £40m in genetic research as part of the UK Government’s life sciences sector deal.
Drug Research > Drug Discovery & Development > News
Fate Therapeutics, University of California San Diego launch CAR NK Cancer immunotherapy collaboration
Fate Therapeutics has partnered with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies.
Drug Research > Drug Discovery & Development > News
Carmot, Amgen form drug discovery partnership
Carmot Therapeutics has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen. The collaboration intends to identify novel molecules aimed for Parkinson’s disease.
Drug Research > Drug Discovery & Development > News
Researchers show aspirin added to cancer drug improves effectiveness
Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.
Drug Research > Drug Discovery & Development > News
Blue Oak, PsychoGenics enter into drug discovery partnership
Blue Oak Pharmaceuticals and PGI Drug Discovery (PsychoGenics) have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.
Drug Research > Drug Discovery & Development > News
Astellas Pharma acquires Mitobridge for $225m
Astellas Pharma has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their research and development (R&D) collaboration focused on discovering and developing novel drugs that target mitochondrial function.
Drug Research > Drug Discovery & Development > News
I-Mab Biopharma partners with MorphoSys on cancer investigational medicine
I-Mab Biopharma and MorphoSys have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.
Drug Research > Drug Discovery & Development > News
resTORbio raises $40m from biotech and institutional investors
resTORbio, a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of aging-related diseases, has raised $40m in a Series B financing round.
Drug Research > Drug Discovery & Development > News
1-15 of 4547 results